BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31685755)

  • 1. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
    Miyake T
    Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
    Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
    Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
    Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
    Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
    Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
    Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.
    Zamek-Gliszczynski MJ; Goldstein KM; Paulman A; Baker TK; Ryan TP
    Drug Metab Dispos; 2013 Jun; 41(6):1174-8. PubMed ID: 23569176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
    Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
    Agarwal S; Uchida Y; Mittapalli RK; Sane R; Terasaki T; Elmquist WF
    Drug Metab Dispos; 2012 Jun; 40(6):1164-9. PubMed ID: 22401960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
    Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
    Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
    Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
    Gong IY; Mansell SE; Kim RB
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
    Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
    J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.